A Study of PYX-201 in Advanced Solid Tumors
← catalyst calendarNCT05720117 · readout in 249 d
Sponsored by Pyxis Oncology, Inc (industry) · PYXS — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
330estimated
Sites
29
Countries
Belgium, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-14 | actual | When the study began enrolling |
| Primary completion | 2027-04-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor
- Advanced Solid Tumor
Intervention
- Drug: PYX-201
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants who Experience a Dose-limiting Toxicity (DLT) in Dose Escalation
measured Day 1 to Day 21
Safety and Tolerability as assessed by adverse event monitoring for participants in Dose Escalation
measured Up to approximately 3 years
Objective Response Rate (ORR) observed in participants in Dose Expansion
measured Up to approximately 2 years
Permalink · PYXS's whole pipeline · Catalyst calendar · Every registered study · What changed